repotrectinib news

All news on repotrectinib (also known as TPX-0005 and Augtyro): plants, production capacities, investments and involved companies.

16 September 2026

Chugai: FoundationOne CDx approved as companion diagnostic for tovorafenib in BRAF‑altered/fusion glioma

Approval allows FoundationOne CDx to detect BRAF V600 alterations and BRAF fusion genes to guide tovorafenib treatment in glioma and expands companion indications to nine cancer types.

Who will be producing repotrectinib in the future?

Find out with chemXplore Alpha

Learn more